Medical Countermeasures
Abstract
To further develop an expedited medical countermeasure capability, emerging technologies will be integrated to address the safety and efficacy considerations in the risk/benefit package necessary to successfully counter naturally emerging or engineered biological warfare threats and new emerging infectious threats. These technologies will also be focused on reduction of time, risk, and cost associated with new therapeutic development. For example, this program will develop in vitro tissue constructs (IVTC) that will emulate human response to therapeutic compounds, thereby significantly reducing the cost and time for evaluating safety and efficacy of therapeutics.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2014
- Source ID
- 92fabbcd3ded5ecb2d4aef6a5e614354